Series A · BiotechN-Zyme Biomedical: Series ADeveloping first-in-class therapies targeting pepsin for reflux diseasePublished Oct 4, 2026By RoundOS Funding deskFunding historyJul 22, 2026Series A · This round$4.6MSourcesbusinesswire.com↗
MetriportOpen-source healthcare data infrastructure unifying patient records for clinicians$26MSeries A · Aug 27, 2026
AusperBioDevelops oligonucleotide therapeutics targeting chronic hepatitis B$120MSeries C · Aug 27, 2026
ProFound TherapeuticsUses AI and proteomics to discover drug targets and biomarkers for preeclampsia and eclampsia$35MStrategic · Aug 27, 2026
ArintraAI platform automating medical coding and revenue assurance for health systems$25MSeries B · Aug 26, 2026